Logo image of HALO

HALOZYME THERAPEUTICS INC (HALO) Stock Price, Quote, News and Overview

NASDAQ:HALO - Nasdaq - US40637H1095 - Common Stock - Currency: USD

56.77  +0.49 (+0.87%)

After market: 56.77 0 (0%)

HALO Quote, Performance and Key Statistics

HALOZYME THERAPEUTICS INC

NASDAQ:HALO (2/4/2025, 8:00:01 PM)

After market: 56.77 0 (0%)

56.77

+0.49 (+0.87%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High65.53
52 Week Low34.36
Market Cap7.22B
Shares127.23M
Float125.87M
Yearly DividendN/A
Dividend YieldN/A
PE14.98
Fwd PE11.02
Earnings (Next)02-25 2025-02-25/amc
IPO01-30 2003-01-30


HALO short term performance overview.The bars show the price performance of HALO in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 5 -5 10 15

HALO long term performance overview.The bars show the price performance of HALO in the last 1, 2 and 3 years. 1 year 2 years 3 years 20 40 60

The current stock price of HALO is 56.77 USD. In the past month the price increased by 18.92%. In the past year, price increased by 59.96%.

HALOZYME THERAPEUTICS INC / HALO Daily stock chart

HALO Latest News, Press Releases and Analysis

News Image
2 days ago - Chartmill

HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is a candidate for high growth investors. Here's why.

A fundamental and technical analysis of (NASDAQ:HALO): HALOZYME THERAPEUTICS INC (NASDAQ:HALO) may be suited for high growth investing, we'll explore why in this article.

News Image
2 days ago - Chartmill

NASDAQ:HALO—A High-Growth Stock Gearing Up for Its Next Upward Move.

Based on fundamental and technical analysis of NASDAQ:HALO we ask: Why HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Is a Standout High-Growth Stock in a Consolidation Phase.

News Image
9 days ago - Chartmill

In the world of growth stocks, NASDAQ:HALO shines as a value proposition.

HALOZYME THERAPEUTICS INC was identified as an affordable growth stock. NASDAQ:HALO is showing great growth, but also scores well on profitability. At the same time it seems to be priced reasonably.

News Image
12 days ago - Chartmill

In a market where value is scarce, NASDAQ:HALO offers a refreshing opportunity with its solid fundamentals.

HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.

News Image
15 hours ago - Halozyme Therapeutics, Inc.

Halozyme to Report Fourth Quarter and Full Year 2024 Financial and Operating Results

/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its fourth quarter and full year 2024 financial and...

HALO Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.77 335.67B
AMGN AMGEN INC 15.04 155.36B
VRTX VERTEX PHARMACEUTICALS INC 945.65 124.20B
GILD GILEAD SCIENCES INC 22.12 122.12B
REGN REGENERON PHARMACEUTICALS 15.34 76.60B
ARGX ARGENX SE - ADR N/A 38.95B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 34.95B
BNTX BIONTECH SE-ADR N/A 28.08B
ONC BEIGENE LTD-ADR N/A 23.76B
NTRA NATERA INC N/A 23.00B
BIIB BIOGEN INC 8.73 20.76B
UTHR UNITED THERAPEUTICS CORP 15.52 15.78B

About HALO

Company Profile

HALO logo image Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. The company is headquartered in San Diego, California and currently employs 373 full-time employees. The company went IPO on 2003-01-30. The Company’s ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, its commercially validated solution is used to facilitate the subcutaneous (SC) delivery of injected drugs and fluids, with a focus on reducing treatment burden for patients. The company also develops, manufactures, and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The firm has two commercial proprietary products, Hylenex and XYOSTED, partnered commercial products and ongoing product development programs with several pharmaceutical companies. The company markets and sells Hylenex recombinant, which is a formulation of rHuPH20. The company markets and sells its proprietary product XYOSTED for SC administration of testosterone replacement therapy (TRT) in adult males.

Company Info

HALOZYME THERAPEUTICS INC

12390 El Camino Real

San Diego CALIFORNIA 92121-1345 US

CEO: Helen I. Torley

Employees: 373

Company Website: https://www.halozyme.com/

Investor Relations: https://ir.halozyme.com/

Phone: 18587948889

HALO FAQ

What is the stock price of HALO?

The current stock price of HALO is 56.77 USD.


What is the symbol for HALOZYME THERAPEUTICS INC stock?

The exchange symbol of HALOZYME THERAPEUTICS INC is HALO and it is listed on the Nasdaq exchange.


On which exchange is HALO stock listed?

HALO stock is listed on the Nasdaq exchange.


Is HALO a good stock to buy?

Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for HALO, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of HALO.


Does HALO stock pay dividends?

HALO does not pay a dividend.


When does HALO stock report earnings?

HALO will report earnings on 2025-02-25, after the market close.


What is the Price/Earnings (PE) ratio of HALO?

The PE ratio for HALO is 14.98. This is based on the reported non-GAAP earnings per share of 3.79 and the current share price of 56.77 USD.


What is the Short Interest ratio of HALO stock?

The outstanding short interest for HALO is 7.47% of its float.


HALO Technical Analysis

ChartMill assigns a technical rating of 10 / 10 to HALO. When comparing the yearly performance of all stocks, HALO is one of the better performing stocks in the market, outperforming 87.51% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

HALO Fundamental Analysis

ChartMill assigns a fundamental rating of 7 / 10 to HALO. HALO has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

HALO Financial Highlights

Over the last trailing twelve months HALO reported a non-GAAP Earnings per Share(EPS) of 3.79. The EPS increased by 55.33% compared to the year before.


Industry RankSector Rank
PM (TTM) 41.43%
ROA 18.53%
ROE 86.69%
Debt/Equity 3.32
Chartmill High Growth Momentum
EPS Q2Q%69.33%
Sales Q2Q%34.28%
EPS 1Y (TTM)55.33%
Revenue 1Y (TTM)21.36%

HALO Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 76% to HALO. The Buy consensus is the average rating of analysts ratings from 15 analysts.

For the next year, analysts expect an EPS growth of 51.47% and a revenue growth 20.86% for HALO


Ownership
Inst Owners99.18%
Ins Owners0.97%
Short Float %7.47%
Short Ratio6.32
Analysts
Analysts76
Price Target66.05 (16.35%)
EPS Next Y51.47%
Revenue Next Year20.86%